Table 1.

Univariate analysis and multivariate analysis of the correlation of the expression of CEP55 and SHCBP1 with OS among glioma patients.

Parameter	Univariate analysis			Multivariate analysis
				1			2
	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Age (increasing years)	1.08	1.07-1.10	2.70 E -32	1.05	1.03-1.07	3.37 E -09	1.05	1.03-1.07	1.02 E -09
Gender (male vs. female)	0.95	0.69-1.32	0.795	0.95	0.67-1.34	0.769	0.92	0.65-1.31	0.653
Grade (increasing tumor grade)	5.15	3.92-6.76	4.33 E -32	1.86	1.32-2.66	0.000	1.88	1.33-2.65	0.000
Mutation count (increasing number)	1.00	1.00-1.00	0.340	0.99	0.98-1.00	0.169	0.99	0.98-1.00	0.125
IDH status (mutant ion vs. wild)	0.10	0.07-0.14	5.85 E -36	0.17	0.07-0.44	0.000	0.19	0.08-0.49	0.001
1p/19q codeletion (yes vs. no)	0.24	0.14-0.41	1.60 E -07	0.70	0.24-2.02	0.506	0.70	0.24-2.46	0.521
MGMT promoter status (methylated vs. unmethylated)	0.31	0.22-0.43	2.65 E -12	0.94	0.63-1.43	0.800	0.90	0.60-1.35	0.598
Chr 7 gain/Chr 10 loss (yes vs. no)	7.97	5.44-11.7	1.98 E -26	1.04	0.67-1.61	0.852	1.07	0.69-1.67	0.753
Chr 19/20 cogain (yes vs. no)	2.72	1.46-5.06	0.002	0.46	0.23-0.91	0.026	0.44	0.22-0.88	0.020
TERT expression status (yes vs. no)	2.37	1.69-3.32	6.30 E -07	1.45	0.78-2.69	0.236	1.38	0.74-2.57	0.307
ATRX status (mutant ion vs. wild)	0.44	0.30-0.65	3.16 E -05	2.16	0.89-5.24	0.088	2.17	0.90-5.23	0.084
CEP55 (increasing number)	2.26	1.94-2.64	8.37 E -26	1.28	0.97-1.68	0.076
SHCBP1 (increasing number)	2.77	2.31-3.32	4.95 E -28				1.40	1.04-1.88	0.025

1 and 2 represent the results of multivariate analysis of CEP55 and SHCBP1, respectively. Bold values indicate p < 0.05. HR: hazard ratio; OS: overall survival; CI: confidence interval.